Search Results - "Iskierka‐Jażdżewska, E."

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma by Kim, T M, Taszner, M, Novelli, S, Cho, S-G, Villasboas, J C, Merli, M, Jiménez-Ubieto, A, Tessoulin, B, Poon, L M, Tucker, D, Walewski, J, Yi, S, Song, Y, Chong, G, Bachy, E, Guidez, S, Alonso, A, Jagadeesh, D, Zhang, W, Magnano, L, Iskierka-Jażdżewska, E, Tani, M, Shen, B, Uppala, A, Zhu, M, Shariff, S, Brouwer-Visser, J, Chaudhry, A, Mohamed, H, Ambati, S, Luminari, S

“…Odronextamab, a CD20×CD3 bispecific antibody that engages cytotoxic T cells to destroy malignant B cells, has demonstrated encouraging activity across multiple…”
Get more information

P677: CLINICAL EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP by Soboń, A., Drozd‐Sokołowska, J., Paszkiewicz‐Kozik, E., Popławska, L., Morawska, M., Tryc‐Szponder, J., Bołkun, L., Rybka, J., Pruszczyk, K., Juda, A., Majeranowski, A., Iskierka‐Jażdżewska, E., Steckiewicz, P., Wdowiak, K., Budziszewska, B., Jamroziak, K., Hus, I., Lech‐Marańda, E., Puła, B.

Get full text

P1221: DIFFUSE LARGE B‐CELL LYMPHOMA RICHTER SYNDROME IN CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN POLISH ADULT LEUKEMIA STUDY GROUP by Sośnia, O., Danecki, M., Wąsik‐Szczepanek, E., Tryc‐Szponder, J., Iskierka‐Jażdżewska, E., Majeranowski, A., Pruszczyk, K., Krzemień, H., Bołkun, L., Paszkiewicz‐Kozik, E., Drozd‐Sokołowska, J., Kwiatkowski, J., Wiśniewska‐Organek, D., Budziszewska, B., Jamroziak, K., Hus, I., Lech‐Marańda, E., Puła, B.

Get full text

Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma by Obazee, O., Archibugi, L., Andriulli, A., Soucek, P., Małecka‐Panas, E., Ivanauskas, A., Johnson, T., Gazouli, M., Pausch, T., Lawlor, R. T., Cavestro, G. M., Milanetto, A. C., Di Leo, M., Pasquali, C., Hegyi, P., Szentesi, A., Radu, C. E., Gheorghe, C., Theodoropoulos, G. E., Bergmann, F., Brenner, H., Vodickova, L., Katzke, V., Campa, D., Strobel, O., Kaiser, J., Pezzilli, R., Federici, F., Mohelnikova‐Duchonova, B., Boggi, U., Lemstrova, R., Johansen, J. S., Bojesen, S. E., Chen, I., Jensen, B. V., Capurso, G., Pazienza, V., Dervenis, C., Sperti, C., Mambrini, A., Hackert, T., Kaaks, R., Basso, D., Talar‐Wojnarowska, R., Maiello, E., Izbicki, J. R., Cuk, K., Saum, K. U., Cantore, M., Kupcinskas, J., Palmieri, O., Delle Fave, G., Landi, S., Salvia, R., Fogar, P., Vashist, Y. K., Scarpa, A., Vodicka, P., Tjaden, C., Iskierka‐Jazdzewska, E., Canzian, F.

“…Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have previously been implicated in familial pancreatic ductal…”
Get full text

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2 by Poon, M., Walewski, J., Kim, T. M., Cho, S., Jarque, I., Iskierka‐Jażdżewska, E., Prince, H. M., Oh, S. Y., Lim, F., Carpio, C., Tan, T., Ayyappan, S., Gutierrez, A., Li, J., Ufkin, M., Zhu, M., Chaudhry, A., Mohamed, H., Ambati, S., Kim, W. S.

Get full text